MannKind reported $668K in Net Income for its fiscal quarter ending in June of 2025.


Net Income Change Date
Adma Biologics USD 34.22M 77.68M Jun/2025
Dynavax Technologies USD 18.72M 114.82M Jun/2025
Eli Lilly USD 5.66B 2.9B Jun/2025
Halozyme Therapeutics USD 165.16M 47.06M Jun/2025
Insmed USD -321686000 65.1M Jun/2025
MacroGenics USD -36250000 20.83M Jun/2025
MannKind USD 668K 12.49M Jun/2025
Merck USD 4.43B 652M Jun/2025
Novo Nordisk DKK 29.03B 1.73B Mar/2025
Pfizer USD 2.91B 58M Jun/2025
Sanofi EUR 3.94B 2.07B Jun/2025
Xencor USD -30825000 17.59M Jun/2025